Please, look at Ryanodex case and summarize the basis for Priority review
Ryanodex has previously been granted Orphan Drug status and the company currently owns three US patents covering the product.
Eagle Pharmaceuticals believes that the immediate benefits of its improved and more concentrated formulation can be clinically significant in critical care situations.
"Each vial of Ryanodex is reconstituted in less than one minute by the anesthesiologist in contrast to the need to mix and administer approximately 12 vials of currently marketed products”
This reduction in the time to treat patients can result in notable improvement in patient outcomes. Additionally, the currently marketed formulation requires significant drug product volume to be administered.
NOTICE: it’s more of regulatory affairs and health policy than medicine and health
Use the order calculator below and get started! Contact our live support team for any assistance or inquiry.
[order_calculator]